The clinical trial pool for Johnson & Johnson was diverse. In the United States, 74 percent were White/Caucasian; 15 percent were Hispanic/Latinx; 13 percent were Black/African American; 6 percent were Asian and 1 percent were Native American.
Forty-one percent of participants in the study had health conditions associated with an increased risk for developing severe COVID-19, including obesity (28.5 percent), type 2 diabetes (7.3 percent), hypertension (10.3 percent) and HIV (2.8 percent).
Other immunocompromised participants were also in the study.